Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5241-5250 Newer>

Pharmaceutical Executive October 1, 2008	The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role?
The Motley Fool November 17, 2008 Brian Orelli	Beauty Can Be a Beast Pinched pocketbooks are likely to hurt cosmetic-pharmaceutical companies more than any FDA warning.
The Motley Fool November 17, 2008 Brian Orelli	The Little Chemotherapy That Could Abraxis BioScience has a lot of potential, but, in this market, the company is going to have to show investors that it can make it over the hill before they're going to jump on board.
The Motley Fool November 17, 2008 Rich Smith	This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two.
Chemistry World November 14, 2008 Hepeng Jia	Traditional Chinese medicine firm struggles for approval HSR has spent the past eight years developing Fufang Sanhuangsan, which contains compounds derived from several plants including skullcap, dandelion and bupleurum.
The Motley Fool November 14, 2008 Brian Orelli	Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells.
The Motley Fool November 14, 2008 Brian Orelli	Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
IndustryWeek December 1, 2008 Jill Jusko	Focus on the Process Industries: Pharmaceuticals: Reworking the Pharma Supply Chain As multiple forces challenge the pharmaceutical industry, supply chains get a new look.
The Motley Fool November 12, 2008 Brian Orelli	Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash.
<Older 5241-5250 Newer> Return to current articles.